




RealRate

PHARMACEUTICAL 2022

NovaBay Pharmaceuticals Inc.
Rank 205 of 475



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



PHARMACEUTICAL 2022

NovaBay Pharmaceuticals Inc.
Rank 205 of 475



The relative strengths and weaknesses of NovaBay Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of NovaBay Pharmaceuticals Inc. compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 164% points. The greatest weakness of NovaBay Pharmaceuticals Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 78% points.

The company's Economic Capital Ratio, given in the ranking table, is -66%, being 211% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	13,170
Cost of Goods Sold	2,776
Intangible Assets	9,728
Liabilities, Current	3,442
Liabilities, Non-Current	246
Other Assets	887
Other Compr. Net Income	0
Other Expenses	2,608
Other Liabilities	10,119
Other Net Income	-1,577
Property and Equipment	193
Research and Development	44
Revenues	8,421
Selling, General and Administrative Expense	7,240

Output Variable	Value in 1000 USD
Assets	23,978
Liabilities	13,807
Expenses	12,668
Stockholders Equity	10,171
Net Income	-5,824
Comprehensive Net Income	-5,824
Economic Capital Ratio	-66%

